Influenza diagnostic market highlights key trends and growth drivers

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Influenza Diagnostic Market Be By 2030 Compared To Its 2026 Market Size?

The influenza diagnostic market has experienced robust expansion over recent years. The market is projected to expand from $2.87 billion in 2025 to $3.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this historical growth include seasonal influenza outbreaks, the widespread adoption of rapid antigen tests, the expansion of hospital laboratory infrastructure, government influenza surveillance programs, and heightened awareness regarding early flu diagnosis.

The influenza diagnostic market size is projected to experience substantial expansion in the coming years. By 2030, its valuation is set to reach $4.19 billion, exhibiting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period stems from factors such as an increasing occurrence of influenza epidemics, a heightened need for precise molecular diagnostics, the proliferation of point-of-care testing sites, enhanced public health readiness programs, and innovations in rapid diagnostic assay technology. Key developments expected within the forecast timeframe encompass an escalating demand for quick influenza tests, wider acceptance of molecular diagnostic approaches, a growing inclination towards point-of-care flu diagnostic solutions, the broadening scope of seasonal and pandemic surveillance testing, and ongoing enhancements in test sensitivity and specificity.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

What Major Factors Are Driving The Influenza Diagnostic Market Forward?

The increasing financial investment in research for influenza diagnostics is anticipated to drive the expansion of the influenza diagnostic market moving forward. This funding represents monetary support allocated by government agencies, institutions, and organizations to facilitate scientific investigations aimed at developing, improving, and validating methods and technologies for identifying influenza viruses. The growth in influenza research funding is motivated by insights from the COVID-19 pandemic and concerns about potential future respiratory disease outbreaks, as health authorities recognize the crucial importance of rapid and accurate diagnostic tools to prevent broad transmission and enable timely public health interventions. This augmented research funding aids in the development and commercialization of advanced testing technologies, molecular assays, point-of-care devices, and improved laboratory procedures, which allow for faster and more accurate detection of influenza strains in clinical settings. For instance, in October 2024, the Department of Health and Aged Care, an Australia-based government organization responsible for health research, funding, promotion, and regulation, reported that the Australian Government is dedicating $95 million to combat avian influenza, thereby protecting agriculture, wildlife, and the economy. Therefore, the growing funding for research on influenza diagnostics is fueling the growth of the influenza diagnostic market.

What Are The Key Segment Divisions In The Influenza Diagnostic Market Segment Structure?

The influenza diagnostic market covered in this report is segmented –

1) By Traditional Diagnostic Tests: Rapid Influenza Diagnostic Tests (RIDT), Viral Culture, DFA, Serological Assays, Other Traditional Diagnostic Tests

2) By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests

3) By End User: Hospitals And Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

Subsegments:

1) By Rapid Influenza Diagnostic Tests (RIDT): Immunoassay-based Tests, Lateral Flow Assays, Enzyme Immunoassays (EIA)

2) By Viral Culture: Cell Culture, Egg-based Culture

3) By Serological Assays: Hemagglutination Inhibition (HI) Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting Assay

4) By Other Traditional Diagnostic Tests: Polymerase Chain Reaction (PCR), Immunofluorescence Assays

Which Trends Are Impacting The Progress Of The Influenza Diagnostic Market?

Leading companies in the influenza diagnostic market are developing innovative products, such as the Lucira COVID-19 & Flu Home Test, to enable rapid and simultaneous qualitative detection. This Lucira COVID-19 and Flu Home Test is a single-use, at-home kit that delivers results from self-collected nasal swab samples in approximately 30 minutes. For example, in February 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval for the Lucira COVID-19 & Flu Home Test. The test is designed to identify influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19.

Which Organizations Are Engaged In The Influenza Diagnostic Market?

Major companies operating in the influenza diagnostic market are F. Hoffmann-La Roche Ltd., Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic Inc., Becton Dickinson and Company, DiaSorin SpA, Luminex Corporation, Meridian Bioscience Inc., GenMark Diagnostics Inc., SA Scientific Ltd., Sekisui Diagnostics LLC, bioMérieux Inc., Danaher Corporation, Siemens Healthineers AG, Coris Bioconcept Sprl, Mast Group, Elitech Technology lnc., Analytik Jena AG, altona Diagnostics GmbH, Tecan Trading AG, Genome Diagnostics Pvt Ltd., Germaine Laboratories Inc., Response Biomedical Corporation, TAUNS Laboratories Inc., TRUPCR Europe Ltd., Quest Diagnostics Inc., Labcorp Employer Services Inc.

Get The Full Influenza Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Which Region Is The Leading Market For The Influenza Diagnostic Market?

North America was the largest region in the influenza diagnostics market in 2025. Western Europe was the second largest region in the influenza diagnostics market. The regions covered in the influenza diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Influenza Diagnostic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Browse Through More Reports Similar to the Global Influenza Diagnostic Market 2026, By The Business Research Company

Infectious Disease Diagnostics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795